Risk factor
Weak & very vulnerable to price shocks
Profitability factor
Very low or no dividends
About
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat...
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is neutral on EV/EBITDA.
Target Price
The average target price of BNTX is 137 and suggests 52% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell